Endocrinology · Metabolic Bone Disease
The facts most likely to be tested
Osteopenia is defined by a DEXA scan showing a T-score between -1.0 and -2.5.
The FRAX tool is the gold standard for calculating the 10-year probability of a major osteoporotic fracture to guide treatment decisions.
Universal screening for bone density via DEXA scan is recommended for all women aged 65 and older.
Pharmacologic intervention is indicated for osteopenia patients if the FRAX 10-year hip fracture risk is ≥3% or the major osteoporotic fracture risk is ≥20%.
First-line pharmacologic therapy for patients meeting criteria is bisphosphonates, such as alendronate or risedronate.
Secondary causes of osteopenia, such as hyperparathyroidism, hyperthyroidism, Cushing syndrome, and celiac disease, must be ruled out before diagnosing primary bone loss.
Adequate calcium and vitamin D supplementation is the foundational management for all patients with low bone mass.
Vignette unlocked
A 67-year-old postmenopausal woman presents for a routine physical examination. She has no history of fragility fractures and reports no back pain or loss of height. Her medical history is significant for controlled hypertension and mild GERD. A DEXA scan is performed, revealing a T-score of -1.8 at the femoral neck. Her FRAX score indicates a 10-year probability of hip fracture of 4%.
What is the most appropriate management for this patient?
Initiation of bisphosphonate therapy
The patient meets the criteria for pharmacologic treatment because her FRAX 10-year hip fracture risk is ≥3%, despite her T-score falling within the osteopenia range.
Full handout
High yield triage
Etiology / Epidemiology
Common in postmenopausal women and patients on chronic glucocorticoids. Defined by low bone mass preceding osteoporosis.
Clinical Manifestations
Usually asymptomatic until fracture occurs. Look for silent loss of bone density on screening.
Diagnosis
Gold standard is DEXA scan showing a T-score between -1.0 and -2.5.
Treatment
First-line is Calcium and Vitamin D supplementation and weight-bearing exercise. Avoid smoking.
Prognosis
Risk of progression to osteoporosis; monitor with serial DEXA scans every 3-5 years.
Full handout
Epidemiology & Etiology
Prevalence increases with age, particularly in Caucasian and Asian females. Secondary causes include hyperthyroidism, Cushing syndrome, and prolonged use of glucocorticoids. Lifestyle factors include smoking and excessive alcohol intake.
Pertinent Anatomy
Bone remodeling occurs at the trabecular and cortical surfaces. Osteopenia reflects a reduction in bone mineral density (BMD) primarily in the hip and lumbar spine.
Pathophysiology
Imbalance between osteoclast-mediated bone resorption and osteoblast-mediated bone formation. Chronic negative calcium balance leads to decreased mineralized matrix. This state represents a precursor to osteoporosis where structural integrity is compromised.
Clinical Manifestations
Patients are typically asymptomatic and lack physical exam findings. Red flags include pathologic fractures following minimal trauma. Chronic back pain may suggest vertebral compression fractures.
Diagnosis
The DEXA scan (Dual-energy X-ray absorptiometry) is the gold standard. Diagnosis is confirmed by a T-score between -1.0 and -2.5. A T-score of -2.5 or lower indicates progression to osteoporosis.
Treatment
Management focuses on lifestyle modification: weight-bearing exercise and smoking cessation. Supplementation with Calcium (1200mg/day) and Vitamin D (800-1000 IU/day) is standard. Bisphosphonates are generally reserved for patients with high fracture risk (FRAX score).
Prognosis
Primary goal is preventing progression to osteoporosis. Serial DEXA scans are required every 3-5 years to monitor BMD stability.
Differential Diagnosis
Osteoporosis: T-score ≤ -2.5
Osteomalacia: Defective mineralization due to Vitamin D deficiency
Multiple Myeloma: Lytic lesions on imaging
Hyperparathyroidism: Elevated PTH and hypercalcemia
Paget Disease: Elevated alkaline phosphatase with mosaic bone pattern